The prognosis of patients with metastatic breast cancer (MBC) mainly depends on several patient and tumour characteristics such as age, hormone receptor and HER2 status, histological grade, site of metastasis and performance status, (PS; [@bib8]; [@bib13]), which in the daily practice influence clinical decisions.

Recent studies have shown that the detection of cytokeratin-expressing (CK^+^) cancer cells in the blood (circulating tumour cells (CTCs)) or bone marrow (disseminated tumour cells) also holds significant prognostic information for patients with breast cancer. Indeed, the detection of peripheral blood CK-19mRNA-positive CTCs in patients with early disease has been proven as an independent prognostic factor for reduced disease-free survival (DFS) and overall survival (OS) ([@bib25], [@bib24]; [@bib34], [@bib33], [@bib31]; [@bib17]). Moreover, a pooled analysis showed that bone marrow CK-positive disseminated tumour cells, detected in 31% of stage I--III breast cancer patients, have an independent prognostic impact ([@bib7]). Similarly, in the metastatic setting, [@bib10], using the CellSearch platform, reported that the detection of ⩾5 CTCs/7.5 ml blood at baseline and before the administration of front-line or second-line treatment was associated with a poor clinical outcome both in terms of progression-free survival (PFS) and OS. These findings were further confirmed by several other investigators using either the CellSearch ([@bib9]; [@bib12]; [@bib21]) or immunocytochemical assays ([@bib4]). In addition, the prognostic value of CTCs, as detected by the CellSearch system, was unrelated to hormonal receptor status, site of recurrence, previous treatments or the tumour burden ([@bib9]; [@bib12]; [@bib21]).

Our group, using a molecular (real-time PCR (RT-PCR)) assay, based on the detection of CK-19mRNA transcripts in peripheral blood mononuclear cells (PBMCs) of patients with early-stage breast cancer ([@bib24]), demonstrated in a cohort of 444 patients that their detection was an independent factor associated with an increased risk of relapse and disease-related death ([@bib34], [@bib33]; [@bib17]). In addition, it was shown that adjuvant chemotherapy does not always eliminate CK-19mRNA-positive CTCs, and that patients with chemotherapy-resistant CTCs have an extremely reduced median DFS and OS ([@bib31]). As clinical relapses are believed to be originated from these chemotherapy- and hormone-resistant CK-19mRNA-positive CTCs ([@bib32]), we sought to determine the clinical relevance of the detection of these cells in patients with newly diagnosed MBC, before the initiation of front-line chemotherapy, using the same RT-PCR assay.

Patients and methods
====================

Patients and clinical samples
-----------------------------

A longitudinal trial for the study of micrometastatic disease in breast cancer is ongoing in our Department since 1997. All consenting patients are assessed for the presence of CK-19mRNA CTCs as part of their laboratory evaluation at the time of staging of their recurrent or newly diagnosed metastatic disease and before starting any systemic treatment. In this retrospective, single-centre study, a total of 298 consecutive patients with MBC and sample available for CK-19mRNA determination, who were treated in our Department with first-line chemotherapy during the period from February 1997 to June 2009 were included in the current analysis. During the same period, 393 patients were treated with first-line chemotherapy. Patients who received front-line hormonal therapy were excluded from this analysis. Patients had to have measurable or evaluable disease and a PS of 0--3 (ECOG). Prior adjuvant chemotherapy was allowed, provided that disease relapse occurred at least 12 months (mo) after its completion. Patients presenting a clinical relapse during adjuvant hormone therapy were also eligible, provided that it occurred at least 12 mo after the completion of adjuvant chemotherapy. The oestrogen receptor (ER) and the progesterone receptor (PR) status of primary tumours were determined by immunocytochemistry. The assessment of HER2 expression was evaluated using the HercepTest (Dako, Glostrup, Denmark) using the DAKO-score guidelines, and samples with score 2+ were further analysed by FISH. All patients were treated with systemic chemotherapy as front-line treatment for their metastatic disease; there was no patient who received front-line hormone treatment. Patients were treated with various standard chemotherapy regimens decided by their responsible physicians according to the disease characteristics; responsible physicians had no access to CTC results. A total of 32 (10.7%) patients received either FEC or AC, 104 (34.9%) a combination of taxane plus anthracycline, 125 (41.9%) a non-anthracycline taxane-based regimen and 37 (12.4%) other regimens; finally, 41 (13.8%) patients received trastuzumab combined with chemotherapy (a taxane-based regimen in 31 and vinorelbine in 10 patients). All clinical data were prospectively collected.

Before the initiation of front-line treatment, patients had complete clinical, biochemical and imaging staging (including computed tomography scans of chest and abdomen, as well as a whole-body bone scan) and serum levels of tumour markers (CEA and/or CA 15.3). Response to treatment was assessed according to the World Health Organization criteria ([@bib19]) with the same techniques that were used at baseline, without knowledge of the CTCs\' results.

Peripheral blood (20 ml in EDTA) was obtained at the middle of vein puncture before the initiation of chemotherapy for the detection of CTCs using the molecular assay, whereas 7.5 ml of blood in CellSave_tubes were used for detection of CTCs using the CellSearch system (Veridex Corporation, Warren, NJ, USA). All patients provided a written informed consent to participate in the study, which had been approved by the Ethics and Scientific Committees of our Institution.

Detection of CTCs by CellSearch
-------------------------------

Samples were maintained at room temperature and processed within 24 h. All evaluations were carried out with no knowledge of the patient\'s clinical status. The standardised CellSearch technique for the detection of CTCs in whole blood has been reported previously ([@bib10]). Briefly, CTCs expressing the epithelial cell adhesion molecule were immunomagnetically enriched and stained with 4,2-diamidino-2-phenylindole dihydrochloride, cytokeratins 8,18,19 and CD45. Circulating tumour cells morphology was confirmed in all cases. Quantitative results were expressed as number of CTCs per 7.5 ml blood.

RNA extraction and real-time RT-PCR assay for CK-19mRNA-positive cells
----------------------------------------------------------------------

Peripheral blood mononuclear cells were obtained by Ficoll-Hypaque gradient-density centrifugation within 2--4 h from vein puncture, and total RNA isolation was carried out in a laminar flow hood under RNAse-free conditions by using Trizol (Invitrogen, Grand Island, NY, USA; [@bib25]). The isolated RNA was dissolved in RNA storage buffer (Ambion, Grand Island, NY, USA) and stored at −80 ^o^C until used. RNA concentration was determined by absorbance reading at 260 nm with the NanoDrop spectophotometer (Wilmington, DE, USA) at the time of CK-19mRNA analysis. RNA integrity was tested by PCR amplification of the *β*-actin housekeeping gene. RNA samples prepared from the MCF-7 breast cancer and ARH-77 leukaemic cell lines were used as positive and negative controls, respectively ([@bib25]).

Reverse transcription of RNA was carried out by synthesising cDNA using the Superscript III Platinum Two-Step qRT-PCR Kit (Invitrogen) according to the manufacturer\'s instructions; the real-time RT-PCR assay, performed in a total volume of 10 *μ*l in the LightCycler glass capillaries, for the detection of CK-19mRNA-positive cells and its analytical methodological details (specificity, sensitivity, cut-off for positivity), the used primers and probes, as well as the cycling protocol have been previously described ([@bib24]). The quality of cDNAs was always evaluated by real-time PCR using the *β*-actin housekeeping gene. The lower detection limit for positivity of the assay was determined to be ⩾0.6 MCF-7 cell equivalents/5 *μ*g RNA for the patients\' PBMCs ([@bib24]). Using this cut-off value, only 2 out of 89 healthy individuals tested were found positive ([@bib24]).

Statistical analysis
--------------------

This is a retrospective analysis aiming to investigate the clinical relevance of the detection of CK-19mRNA-positive CTCs, evaluated prospectively and blindly, at the time of diagnosis of metastatic disease before the initiation of any systemic treatment. Therefore, there was no predetermined sample size estimation in this study because of its observational nature. Progression-free survival was defined as the time elapsed between the date of the administration of the first chemotherapy cycle, and either the date of clinical or radiological progression, or death or the last follow-up. Overall survival was measured from the date of the administration of the first chemotherapy cycle until the date of death or last follow-up. To detect significant differences between survival curves, Log-rank or Breslow tests were used. Cox proportional hazards model for time to event data was used to evaluate the hazard of every important variable, as well as for the construction of a multivariate model, explaining the relative significant influence of the covariates on outcomes (unconditional backwards procedure). The interaction between the prognostic value of the detection of CK-19mRNA and known clinico-pathological prognostic factors was tested using the heterogeneity tests for OS and PFS ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Analysis included contingency tables and *χ*^2^-tests for categorical variables used to assess differences between groups. All statistical tests were carried out at the 5% significance level using the statistical software SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients\' demographics
-----------------------

During the study period, 298 consecutive patients with MBC at first presentation were evaluated for the presence of circulating CK-19mRNA-positive CTCs before the administration of any systemic treatment. The patients\' median age was 59 years (range, 27--83), 218 (73.2%) were post-menopausal and 166 (55.7%) had visceral disease. A total of 136 (45.6%) patients had hormone receptor (either ER or PR)-positive/HER2-negative tumours, 61 (20.5%) HER2-positive tumours (3+ or FISH+) and 66 (22.1%) triple-negative tumours. Another 129 (43.3%) patients had received prior adjuvant treatment, most of them in the context of research protocols of the Hellenic Oncology Research Group, whereas 169 (56.7%) patients were diagnosed with metastatic disease from the beginning. There was no difference in terms of the main clinico-pathological characteristics in patients with detectable and undetectable CK-19mRNA-positive CTCs ([Table 1](#tbl1){ref-type="table"}). At the time of analysis, 16 (5.4%) patients are still in first remission and 58 (19.5%) are alive.

Detection of CTCs by CellSearch and RT-PCR
------------------------------------------

In 44 patients treated from January 2007 to May 2009, the detection of CTCs was performed in parallel using the two different assays. Circulating tumour cells were detected in 17 (38.6%) patients using the CellSearch assay (cut-off, ⩾5 CTCs/7.5 ml), and in 24 (54.6%) using the RT-PCR assay (*P*=0.001). The RT-PCR assay failed to detect CTCs in two (4.5%) patients in whom CellSearch could detect CTCs; conversely, CellSearch failed to detect CTCs in nine (20.5%) patients in whom RT-PCR could detect CTCs ([Table 2](#tbl2){ref-type="table"}). However, there was a statistically significant correlation of the detection of CTCs between the two assays (*r*=0.373, *P*=0.0001). The correlation remained significant when the cut-offs for CTC detection with the CellSearch were set at ⩾1 and ⩾2 CTCs ([Table 2](#tbl2){ref-type="table"}).

Detection of CTCs
-----------------

CK-19mRNA-positive cells were detected in 199 (66.8%) patients. There was no association between the detection of CK-19mRNA-positive CTCs and the menopausal status, the PS, the hormone receptor or HER2/neu status, the presence of visceral or bone metastases and the administered front-line treatment ([Table 1](#tbl1){ref-type="table"}). The median number of CK-19mRNA-positive CTCs was 1.0 MCF-7 cell equivalents/5 *μ*g RNA (range, 0.0--1221.0). Front-line chemotherapy resulted in an objective response (complete plus partial response) in 95 (48.2%) out of 199 patients with detectable CK-19mRNA-positive CTCs and in 58 (58.6%) out of 99 patients without detectable CK-19mRNA-positive CTCs (*P*=0.109). There was no significant correlation between the detection of CTCs and the presence of visceral (53.8% *vs* 59.6% in CK-19mRNA-positive and CK-19mRNA-negative patients, respectively; *P*=0.441) or bone (36.2% and 36.4%, respectively; *P*=0.999) disease.

Clinical outcome according to the detection of CK-19mRNA-positive cells
-----------------------------------------------------------------------

At the time of analysis, 240 (80.5%) patients had died. The median follow-up was 83.3 mo (range, 2.2--119.6). The median PFS was significantly lower in patients with detectable CK-19mRNA-positive CTCs compared with patients without detectable CTCs (9.2 *vs* 11.9 mo; *P*=0.003, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, [Figure 3](#fig3){ref-type="fig"}). The median OS was significantly higher in patients without detectable CK-19mRNA-positive CTCs compared to patients with detectable CTCs (38.9 *vs* 29.7 mo; *P*=0.016, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, [Figure 4](#fig4){ref-type="fig"}).

Univariate and multivariate analysis
------------------------------------

The univariate analysis using the menopausal status, the hormone receptor status (ER and PR), the HER2/neu status, the PS, the disease localisation (bone or visceral), the adjuvant chemotherapy and the detection of CK-19mRNA-positive CTCs at baseline revealed that PS, ER, PR, HER2/neu, adjuvant chemotherapy and CTC status at baseline were significantly associated with PFS ([Table 3](#tbl3){ref-type="table"}). Multivariate analysis demonstrated that only the ER negativity (hazard ratio (HR) 1.627; 95% CI: 1.267--2.090) and the detection of CK-19mRNA-positive CTCs (HR 1.424; 95% CI: 1.092--1.857) could be emerged as independent factors associated with a decreased PFS ([Table 4](#tbl4){ref-type="table"}). Similarly, the univariate analysis for the OS using the same parameters as for PFS, demonstrated that the same factors (PS, ER, PR and CTC status) were significantly associated with OS ([Table 3](#tbl3){ref-type="table"}). Interestingly, although triple-negative histological subtype was not associated with worse outcome in the univariate analysis, when we analysed the prognostic significance of triple-negative histology according to the presence of CTCs, it was shown that triple-negative/CK-19mRNA-positive patients had worse prognosis compared with CK-19mRNA-positive patients with other histological subtypes (median OS 26.6 mo *vs* 32.9 mo, respectively). Multivariate analysis revealed that the ER negativity (HR 1.480; 95% CI: 1.129--1.940), worse PS (HR 1.957; 95% CI: 1.199--3.193) and the detection of CTCs at baseline (HR 1.371; 95% CI: 1.019--1.845) emerged as independent factors associated with a decreased OS ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

The aim of the current study was to evaluate the prognostic value of CK-19mRNA-positive CTCs in women with newly diagnosed recurrent or *de novo* MBC, using our previously described RT-PCR assay, which has been validated in patients with early breast cancer ([@bib24]; [@bib33], [@bib31]; [@bib17]). The results of this retrospective study demonstrate that the detection of CK-19mRNA-positive CTCs at baseline and before the initiation of any systemic treatment is a poor prognostic factor, as it was independently associated with a significantly reduced median PFS and OS.

Recent studies demonstrated the prognostic value of baseline CTCs measurement in MBC. Indeed, the study by [@bib10] demonstrated that the detection of ⩾5 CTCs per 7.5 ml of blood from MBC patients was associated with a shorter PFS and OS, and has superior and independent prognostic value than the tumour burden and disease phenotype. This finding was subsequently confirmed by the same investigators in untreated patients with MBC eliminating factors, which may influence the results (i.e., differences between prior therapies, stage of the disease, line of treatment, etc); in this particular study, CTC measurement performed at baseline and before initial therapy was found to be highly predictive for worse PFS and OS ([@bib11]). In a similar study, [@bib12] confirmed that the detection of \<5 CTCs/7.5 ml of blood at baseline in patients with newly diagnosed MBC was associated with a significantly better OS compared with those with ⩾5 CTCs/7.5 ml of blood, irrespectively of the hormone receptor and HER-2/neu status, site of first metastasis or whether the patient had recurrent or *de novo* metastatic disease. Similar results have been reported by other investigators who evaluated the presence of CTCs using either the CellSearch platform ([@bib3]; [@bib22]) or other techniques ([@bib30]; [@bib4]; [@bib20]). In a recent report, the MD Anderson group reported that the risk of death was linearly increased with increasing CTC count in all molecular tumour subtypes; however, it was higher in ER+ and triple-negative than in HER2+ tumours ([@bib15]).

The detection rate of CK-19mRNA transcripts in peripheral blood was 67% in this group of patients with metastatic disease. Using the same RT-PCR assay, CK-19mRNA-positive CTCs were detected in 181 (40.8%) of 444 patients with early breast cancer ([@bib17]). [@bib28], using a RT-PCR for CK-19mRNA showed that 26% of patients with MBC were CTC-positive, whereas [@bib23] were able to detect CK19+mRNA cells in 56--75% of 86 patients with metastatic disease. Using a multi-marker RT-PCR assay for four marker genes, including *CK-19* ([@bib5]), tumour cells were detected in 31% of patients with advanced breast cancer ([@bib29]), and using the AdnaTest BreastCancer, 52% of metastatic patients were tested positive for CTCs ([@bib26]). It should be mentioned here, however, that the use of various enrichment procedures, the variability in the millilitres of blood analysed, and the different methods used for the evaluation of the sensitivity and specificity of the assays, preclude firm conclusions to be drawn regarding the actual incidence of CTC detection. To further complicate the issue, in the above-mentioned reports, different numbers of patients have been evaluated in different stages of metastatic disease. In the present study, 20 ml of peripheral blood were used to detect CTCs in previously untreated patients with advanced breast cancer. Usually, smaller volumes of blood are used for gene expression studies in metastatic patients, which could explain, at least in part, the relatively high incidence of CTC detection reported here.

Nevertheless, in the present study, the detection of CK-19mRNA-positive CTCs in metastatic patients was significantly and independently associated with worse outcome. The independent prognostic value of CTC detection using this method was observed irrespectively of the quantitative burden of CTCs, as patients were classified according to the presence or the absence of the CK-19mRNA transcripts. The cut-off of ⩾0.6 MCF-7 cell equivalents/5 *μ*g RNA of the patients\' PBMCs, which has been determined in a previous analytical study ([@bib24]) and has been shown to be able to define patients with early breast cancer at high risk for relapse and disease-related death ([@bib33], [@bib31]; [@bib17]), was also revealed appropriate for the selection of poor prognosis patients with newly diagnosed MBC. Despite the fact that no quantitative data have been reported, preliminary results seem to indicate that quantitative classification of patients according to the numerical burden of CTCs is not superior than the qualitative one (data not shown). This might be a difference with the results obtained with the CellSearch platform ([@bib15]). In a small cohort of patients, the detection of CTCs was performed, in parallel, using both the CellSearch platform and the RT-PCR assay; the findings indicate that there was a close correlation concerning the detection of CTCs between the two assays, suggesting that they, probably, recognise similar sub-populations of CTCs. Obviously, the small number of patients limits the statistical power of these comparisons necessitating a comparison of the two assays in a larger number of patients. In any case, this correlation could, at least partly, explain the fact that our findings are in line with those of the literature concerning the independent prognostic value of CTC detection before the initiation of any systemic treatment.

The current study represents the cumulative experience of \>10-year involvement of our group in the study of CK-19mRNA-positive CTCs in patients with early or/and MBC. Our study demonstrates, for the first time, that the detection of CK-19mRNA-positive CTCs in a large group of previously untreated patients with metastatic disease, using a well-validated RT-PCR assay, is clinically relevant, as it was significantly associated with an increased incidence of relapse and disease-related death. The prognostic value of the detection of CK-19mRNA-positive CTCs was independent of whether the patients presented with recurrent or *de novo* MBC or the different well-known clinico-pathological characteristics. Similarly, [@bib23], showed in a smaller group of metastatic patients that the presence of CK19+mRNA CTCs was associated with poor prognosis.

Our findings, taken together with those of the literature, strongly suggest that the detection of CTCs represent an interesting marker characterising the biology of the disease, and thus, might identify subgroups of patients with different prognosis. On the basis of these findings, we strongly support the [@bib12] proposition that CTC\'s status could be used as a new stratification factor for women with newly diagnosed MBC. However, despite these data, CTCs measurement at baseline has not yet been incorporated into cancer-staging protocols or even considered as a 'standard\' clinical tool; the American Society of Clinical Oncology (ASCO) 2007 guidelines ([@bib16]) do not recommend its routine use in clinical practice, owing to insufficient clinical evidence. Nevertheless, [@bib12] proposed that the distinction of the two different prognostic groups of patients with MBC based on the detection of CTCs could provide a biological (and not merely anatomic) distinction of prognoses upfront, on the basis of a reliable and reproducible test (e.g., stage IVA *vs* IVB); in addition, the upfront use of CTCs would allow patients with more aggressive or stage IVB disease to be actively enrolled into clinical trials designed to address specific questions related to the selection of more specific and targeted therapies aimed at the elimination of CTCs, which might have an impact on patients\' survival ([@bib10]; [@bib3], [@bib2]). However, limiting factors such as the variable expression of different epithelial antigens in poorly differentiated tumours, the different sensitivity and specificity of various detection assays, and the lack of their direct comparison support the need for cautious consideration of the use of CTC measurement in the daily clinical practice. We have to wait for the data of the large validation trial, which has been undertaken by the Southwestern Oncology Group to definitively decide on the integration of CTC measurement into clinical practice and to provide the rational for an individualised therapeutic approach. Additionally, the better biological analysis of CTCs may help us to better understand the mechanism of resistance of tumour cells to the different anti-tumour agents, as well as to define new molecular targets for their elimination ([@bib6]). This is most important, as experimental data seem to indicate that the population of CTCs is heterogeneous and an important number of them are apoptotic ([@bib18]), whereas another subpopulation may express stem cell or/and epithelial--mesenchymal transition markers ([@bib14]; [@bib1]; [@bib27]) facilitating the disease dissemination.

In conclusion, the results of the present study demonstrate that the detection of CK-19mRNA-positive CTCs in patients with MBC at baseline and before the initiation of first-line treatment is associated with significant prognostic information. Further prospective studies are needed to investigate whether the genotypic or/and phenotypic characterisation of CTCs may allow a more effective and rational treatment of MBC, which could confer a survival benefit in these patients.
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###### Patients\' demographics and clinico-pathological characteristics

                                              **All patients** ***n*****=300**   **CK-19 (+)** ***n*****=199 (66.8%)**   **CK-19 (--)** ***n*****=99 (33.2%)**   ***χ***^**2**^**-test**
  ------------------------------------------- ---------------------------------- --------------------------------------- --------------------------------------- ----------------------------
  *Age*                                                                                                                                                          Mann--Whitney (*P*-values)
   Median (min-max)                           59.0 (27--83)                      59.0 (27--83)                           60.0 (29--81)                           0.426
                                                                                                                                                                  
  *Menopausal status*                                                                                                                                            
   Pre (%)                                    80 (26.8)                          55 (27.6)                               25 (25.3)                                
   Post (%)                                   218 (73.2)                         144 (72.4)                              74 (74.7)                               0.680
                                                                                                                                                                  
  *Performance status*                                                                                                                                           
   0--1 (%)                                   265 (88.9)                         176 (88.4)                              89 (89.9)                                
   2--3 (%)                                   25 (8.4)                           18 (9.0)                                7 (7.1)                                  
   Missing (%)                                8 (2.7)                            5 (2.5)                                 3 (3.0)                                 0.661
                                                                                                                                                                  
  *Molecular profile*                                                                                                                                            
   ?R- and/or PR-positive/??R2-negative (%)   136 (45.6)                         84 (42.2)                               52 (52.5)                                
   ?R- and/or PR-positive/??R2-positive (%)   25 (8.4)                           13 (6.5)                                12 (12.1)                                
   ?R-/PR-negative/??R2-positive (%)          36 (12.1)                          29 (14.6)                               7 (7.1)                                  
   Triple-negative (%)                        66 (22.1)                          49 (24.6)                               17 (17.2)                                
   Unknown (%)                                35 (11.7)                          24 (12.1)                               11 (11.1)                               0.034
                                                                                                                                                                  
  *Disease location*                                                                                                                                             
   (a) Visceral (%)                           166 (55.7)                         107 (53.8)                              59 (59.6)                                
    Non-visceral (%)                          114 (38.3)                         79 (39.7)                               35 (35.4)                                
    Missing (%)                               18 (6.0)                           13 (6.5)                                5 (5.1)                                 0.441
                                                                                                                                                                  
   (b) Bones (%)                              108 (36.2)                         72 (36.2)                               36 (36.4)                                
    No bones (%)                              182 (57.7)                         114 (57.3)                              58 (58.6)                                
    Missing (%)                               18 (6.0)                           13 (6.5)                                5 (5.1)                                 0.999
                                                                                                                                                                  
  *Adjuvant chemotherapy*                                                                                                                                        
   No (%)                                     169 (56.7)                         105 (52.8)                              64 (64.6)                                
   Yes (%)                                    129 (43.3)                         94 (47.2)                               35 (35.4)                               0.063
                                                                                                                                                                  
  *Front-line chemotherapy*                                                                                                                                      
   Taxane-based (%)                           125 (41.9)                         78 (39.2)                               47 (47.5)                                
   Anthracycline-based (%)                    32 (10.7)                          20 (10.1)                               12 (12.1)                                
   Taxane/anthracycline --based (%)           104 (34.9)                         72 (36.2)                               32 (32.3)                                
   Other (%)                                  37 (12.4)                          29 (14.6)                               8 (8.1)                                 0.276
                                                                                                                                                                  
  *Survival status*                                                                                                                                              
   Alive (%)                                  58 (19.5)                          29 (14.6)                               29 (29.3)                                
   Dead (%)                                   240 (80.5)                         170 (85.4)                              70 (70.7)                               0.003

Abbreviations: ER=oestrogen receptor; PR=progesterone receptor.

###### Comparison of detection of CTCs by both CellSearch and RT-PCR assays

                                          **CellSearch**                                                                                                          
  --------------------------------------- ---------------- ----------------------- ------- ----------------------- ------------ ------- ------------ ------------ -------
  RT-PCR-negative                         12 (27.3%)       8 (18.8%)               0.008   14 (31.8%)              6 (13.6%)    0.003   18 (40.9%)   2 (4.5%)     0.001
  RT-PCR-positive                         5 (11.4%)        19 (43.2%)                      6 (13.6%)               18 (40.9%)           9 (20.5%)    15 (34.1%)    
  Spearman\'s test: *r*=0.385, *P*=0.01                    *r*=0.373, *P*=0.0001           *r*=0.373, *P*=0.0001                                                  

Abbreviations: CTC=circulating tumour cell; RT=real-time PCR.

###### Univariate analysis for PFS and OS

                                          **PFS**   **OS**                                          
  --------------------------------------- --------- -------------- --------- ------- -------------- ---------
  Menopausal status (pre *vs* post)       1.110     0.853--1.446   0.437     1.197   0.903--1.587   0.210
  ER status (− *vs* +)                    1.677     1.308--2.150   \<0.001   1.433   1.098--1.869   0.008
  PR status (− *vs*+)                     1.442     1.118--1.859   0.005     1.334   1.019--1.747   0.036
  HR status (ER(−)/PR(−) *vs* other)      1.641     1.272--2.117   \<0.001   1.385   1.058--1.815   0.018
  HER/2 status (+ *vs* −)                 1.420     1.061--1.900   0.019     1.140   0.831--1.563   0.418
  HR/HER-2 (triple-negative *vs* other)   1.302     0.983--1.724   0.065     1.345   0.996--1.816   0.053
  Adjuvant chemotherapy (yes *vs* no)     1.293     1.019--1.639   0.034     1.254   0.972--1.619   0.082
  Bone disease (yes *vs* no)              0.985     0.769--1.262   0.908     1.210   0.927--1.579   0.161
  Visceral disease (yes *vs* no)          1.093     0.855--1.396   0.478     1.049   0.806--1.365   0.724
  CK-19 pre chemo (+ *vs* −)              1.456     1.132--1.875   0.003     1.406   1.064--1.858   0.016
  Performance status (2--3 *vs* 0--1)     1.667     1.100--2.525   0.016     2.184   1.425--3.347   \<0.001

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; PR=progesterone receptor.

###### Multivariate analysis for PFS and OS

                                        **PFS**   **OS**                                          
  ------------------------------------- --------- -------------- --------- ------- -------------- -------
  ER status (− *vs* +)                  1.627     1.267--2.090   \<0.001   1.480   1.129--1.940   0.005
  Performance status (2--3 *vs* 0--1)                                      1.957   1.199--3.193   0.007
  CK-19 pre chemo (+ *vs* --)           1.424     1.092--1.857   0.009     1.371   1.019--1.845   0.037

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; OS=overall survival; PFS=progression-free survival.
